Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 301 - 350 of 1864 results
- Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.
- Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.
- TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.
- Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
- Thymosin alpha1 suppresses proliferation and induces apoptosis in human leukemia cell lines.
- Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer.
- Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector.
- Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.
- Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
- Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
- Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
- Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen.
- Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects.
- Defective adhesion in tumor infiltrating CD8+ T cells.
- Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells.
- IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy.
- Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus.
- Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
- Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses.
- Immune enhancement and anti-tumour activity of IL-23.
- DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.
- Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
- Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
- Eradication of established tumors in mice by a combination antibody-based therapy.
- Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
- Transferable anticancer innate immunity in spontaneous regression/complete resistance mice.
- Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
- Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.
- Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.
- Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine.
- Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma.
- Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer.
- Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
- Neutralization of interleukin-2 retards the growth of mouse renal cancer.
- IL-23 promotes tumour incidence and growth.
- A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
- Virology- and immunology-based gene therapy for cancer.
- Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner.
- A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors.
- Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells: Enrichment of the vaccine for immunotherapeutic cells.
- Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
- A rapid and efficient in vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of cancer.
- Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice.
- Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
- Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
- Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
- Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer.
- Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
- Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer.